{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medpace Holdings, Inc.
Medpace Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead
Medpace Holdings, Inc. has recently encountered a technical event known as a Death Cross, indicating potential bearish momentum. Despite a strong annual performance with a 64.4% increase, year-to-date results show a decline of 12.85%. Current technical indicators suggest caution as market conditions evolve.
Medpace Holdings Experiences Valuation Adjustment Amid Strong Performance Metrics
Medpace Holdings, Inc. has recently adjusted its valuation, currently showing a P/E ratio of 29 and a notable ROE of 98.27%. Despite facing challenges with negative capital employed, the company has outperformed the S&P 500 over the past year, achieving a return of 41.2%.
Medpace Holdings, Inc. Experiences Revision in Stock Evaluation Amid Competitive Landscape
Medpace Holdings, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 29 and a price-to-book value of 28.11. The company has outperformed the S&P 500 over the past year but has faced a decline year-to-date. Its valuation is higher than some peers, indicating a competitive market landscape.
Medpace Holdings, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics
Medpace Holdings, Inc. has recently adjusted its valuation, with its stock price at $450.41. The company has achieved a 41.67% return over the past year, significantly surpassing the S&P 500. Key metrics include a P/E ratio of 37 and impressive returns on capital and equity, indicating strong performance relative to peers.
Medpace Holdings Hits Day Low of $442.83 Amid Price Pressure
Medpace Holdings, Inc. saw a notable decline in stock value today, contrasting with the broader market. Despite this downturn, the company has shown strong long-term growth, with significant increases in net sales and operating profit. Medpace also maintains a solid market position and high institutional ownership.
Medpace Holdings, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics
Medpace Holdings, Inc. has recently adjusted its valuation, with its current price at $470.59. The company has achieved a 44.47% return over the past year, outperforming the S&P 500. Key metrics include a P/E ratio of 37 and strong returns on capital and equity, indicating robust performance.
Medpace Holdings Hits New 52-Week High at $546.81
Medpace Holdings, Inc. achieved a new 52-week high of USD 546.81 on October 1, 2025, reflecting strong market performance with a 34.07% increase over the past year. The company, with a market cap of USD 13,859 million, demonstrates favorable financial metrics, including a P/E ratio of 21.00 and a return on equity of 242.70%.
Medpace Holdings Reaches New 52-Week High of $514.74
Medpace Holdings, Inc. achieved a new 52-week high of USD 514.74 on September 30, 2025, reflecting strong market performance with a 1-year increase of 26.74%. The company, with a market cap of USD 13,859 million, showcases impressive financial metrics, including a return on equity of 242.70%.
Is Medpace Holdings, Inc. technically bullish or bearish?
As of July 31, 2025, Medpace Holdings, Inc. shows a bullish technical trend with strong momentum indicators, despite some mixed signals in the KST and OBV, and has significantly outperformed the S&P 500 year-to-date and over three years.
Is Medpace Holdings, Inc. overvalued or undervalued?
As of September 3, 2025, Medpace Holdings, Inc. is considered very expensive with a high P/E ratio of 21 compared to peers, despite strong returns, indicating it may be overvalued at its current price of 501.94.
Medpace Holdings Hits New 52-Week High of $506.55, Showcasing Strong Growth
Medpace Holdings, Inc. achieved a new 52-week high of USD 506.55 on September 17, 2025, reflecting strong market performance with a 22.71% increase over the past year. The company, with a market cap of USD 13,859 million, showcases impressive financial metrics, including a return on equity of 242.70%.
Is Medpace Holdings, Inc. overvalued or undervalued?
As of March 5, 2025, Medpace Holdings, Inc. is considered fairly valued with a P/E ratio of 21, an EV to EBITDA of 16.73, and a PEG ratio of 0.59, showing strong operational efficiency compared to peers, despite mixed recent stock performance.
Is Medpace Holdings, Inc. technically bullish or bearish?
As of June 6, 2025, Medpace Holdings, Inc. exhibits a mildly bearish trend, with mixed signals from various indicators, including a mildly bullish weekly MACD and a mildly bearish monthly MACD, alongside bearish daily moving averages and Bollinger Bands.
Who are in the management team of Medpace Holdings, Inc.?
As of March 2022, the management team of Medpace Holdings, Inc. includes Dr. August Troendle (Chairman, President, CEO), Mr. Fred Davenport (Lead Independent Director), and independent directors Mr. Brian Carley, Ms. Ashley Keating, Dr. Thomas King, and Mr. Robert Kraft.
What does Medpace Holdings, Inc. do?
Medpace Holdings, Inc. is a clinical contract research organization that offers drug and medical device development services. As of March 2025, it reported net sales of $559 million and a net profit of $115 million, with a market cap of approximately $8.58 billion.
How big is Medpace Holdings, Inc.?
As of Jun 18, Medpace Holdings, Inc. has a market capitalization of $8.58 billion, with net sales of $2.16 billion and net profit of $416.39 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
